Abbott’s TactiFlex Duo combines pulsed field ablation and radiofrequency energy in one contact-force catheter, giving electrophysiologists a way to move between tissue-selective PFA and conventional thermal ablation without changing platforms during an AFib procedure.
Johnson & Johnson has received U.S. Food and Drug Administration approval for the Dual Energy Thermocool Smarttouch SF Platform, an integrated cardiac ablation system that allows electrophysiologists to deliver both radiofrequency and pulsed field energy through a single catheter. The approval places the Johnson & Johnson MedTech electrophysiology business into a more direct U.S. rollout
Could TN-401 change ARVC treatment strategy? Explore what Tenaya Therapeutics, Inc.’s RIDGE-1 data means for cardiac gene therapy.
Boston Scientific owns the PFA market. Pulse Biosciences just posted 90% one-year AF freedom. Is nanosecond PFA a real disruption or an acquisition target?
Abbott has PFA momentum, but rhythm care is becoming a platform battle. Can clinical data turn into durable adoption?
See how Johnson & Johnson is using CARTOSOUND SONATA and VARIPULSE to reshape electrophysiology workflow and arrhythmia care. Read more.
Johnson & Johnson has presented 12-month pilot data from the OMNY-AF study evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation at the 2026 AF Symposium. The early pilot cohort reported high acute procedural success, no procedure-related adverse events, and a 12-month freedom from atrial fibrillation rate approaching 90 percent. The
Medtronic’s Sphere-360 catheter earns CE Mark and begins U.S. IDE trial. Find out what this means for the future of pulsed field ablation.
Find out how YorLabs’ FDA-cleared ICE platform could transform electrophysiology access and imaging economics in 2026.